Cargando…

Impact of the initial site of metastases on post-recurrence survival for neuroendocrine cervical cancer

OBJECTIVE: To summarize the risk factors and emphasize the prognostic importance of the site of recurrent neuroendocrine cervical cancer (NECC). METHODS: We enrolled 88 patients who developed recurrence after radical surgery for pathological stage I–IVa primary NECC between January 2003 and 30 Decem...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Baoyue, Wan, Ting, Jiang, Yinan, Zheng, Xiaojing, Liu, Pingping, Xiang, Huiling, Zheng, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195210/
https://www.ncbi.nlm.nih.gov/pubmed/35698184
http://dx.doi.org/10.1186/s12885-022-09737-4
_version_ 1784726919311261696
author Pan, Baoyue
Wan, Ting
Jiang, Yinan
Zheng, Xiaojing
Liu, Pingping
Xiang, Huiling
Zheng, Min
author_facet Pan, Baoyue
Wan, Ting
Jiang, Yinan
Zheng, Xiaojing
Liu, Pingping
Xiang, Huiling
Zheng, Min
author_sort Pan, Baoyue
collection PubMed
description OBJECTIVE: To summarize the risk factors and emphasize the prognostic importance of the site of recurrent neuroendocrine cervical cancer (NECC). METHODS: We enrolled 88 patients who developed recurrence after radical surgery for pathological stage I–IVa primary NECC between January 2003 and 30 December 2020 and classified these cases into 7 groups based on the initial recurrence. The risk factors for post-recurrence survival (PRS) were analyzed by Kaplan–Meier and Cox regression methods. RESULTS: Among 88 NECC patients, nearly all patients (95.50%) experienced progression within 3 years. The time to progression was significantly longer in patients with lung recurrence than in patients without lung recurrence (p = 0.008). After the first recurrence, the median follow-up was 11.1 months (range 2.37–65.50 months), and the 5-year PRS was only 20.6%. The depth of invasion in the primary surgery, number of recurrent sites, abdominal organ recurrence were correlated with PRS by univariate analysis. Multivariate analyses revealed that the number of recurrent sites (p = 0.025) and abdominal organ recurrence (p = 0.031) were independent prognostic factors. Notably, the combination of immune checkpoint inhibitors and chemotherapy, with or without surgery, showed a 43.8% objective response rate in recurrent NECC. CONCLUSION: Patients with abdominal organ recurrence need more sophisticated therapy. The combination of immune therapy and chemotherapy might be an opportunity for recurrent NECC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09737-4.
format Online
Article
Text
id pubmed-9195210
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91952102022-06-15 Impact of the initial site of metastases on post-recurrence survival for neuroendocrine cervical cancer Pan, Baoyue Wan, Ting Jiang, Yinan Zheng, Xiaojing Liu, Pingping Xiang, Huiling Zheng, Min BMC Cancer Research OBJECTIVE: To summarize the risk factors and emphasize the prognostic importance of the site of recurrent neuroendocrine cervical cancer (NECC). METHODS: We enrolled 88 patients who developed recurrence after radical surgery for pathological stage I–IVa primary NECC between January 2003 and 30 December 2020 and classified these cases into 7 groups based on the initial recurrence. The risk factors for post-recurrence survival (PRS) were analyzed by Kaplan–Meier and Cox regression methods. RESULTS: Among 88 NECC patients, nearly all patients (95.50%) experienced progression within 3 years. The time to progression was significantly longer in patients with lung recurrence than in patients without lung recurrence (p = 0.008). After the first recurrence, the median follow-up was 11.1 months (range 2.37–65.50 months), and the 5-year PRS was only 20.6%. The depth of invasion in the primary surgery, number of recurrent sites, abdominal organ recurrence were correlated with PRS by univariate analysis. Multivariate analyses revealed that the number of recurrent sites (p = 0.025) and abdominal organ recurrence (p = 0.031) were independent prognostic factors. Notably, the combination of immune checkpoint inhibitors and chemotherapy, with or without surgery, showed a 43.8% objective response rate in recurrent NECC. CONCLUSION: Patients with abdominal organ recurrence need more sophisticated therapy. The combination of immune therapy and chemotherapy might be an opportunity for recurrent NECC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09737-4. BioMed Central 2022-06-14 /pmc/articles/PMC9195210/ /pubmed/35698184 http://dx.doi.org/10.1186/s12885-022-09737-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Pan, Baoyue
Wan, Ting
Jiang, Yinan
Zheng, Xiaojing
Liu, Pingping
Xiang, Huiling
Zheng, Min
Impact of the initial site of metastases on post-recurrence survival for neuroendocrine cervical cancer
title Impact of the initial site of metastases on post-recurrence survival for neuroendocrine cervical cancer
title_full Impact of the initial site of metastases on post-recurrence survival for neuroendocrine cervical cancer
title_fullStr Impact of the initial site of metastases on post-recurrence survival for neuroendocrine cervical cancer
title_full_unstemmed Impact of the initial site of metastases on post-recurrence survival for neuroendocrine cervical cancer
title_short Impact of the initial site of metastases on post-recurrence survival for neuroendocrine cervical cancer
title_sort impact of the initial site of metastases on post-recurrence survival for neuroendocrine cervical cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195210/
https://www.ncbi.nlm.nih.gov/pubmed/35698184
http://dx.doi.org/10.1186/s12885-022-09737-4
work_keys_str_mv AT panbaoyue impactoftheinitialsiteofmetastasesonpostrecurrencesurvivalforneuroendocrinecervicalcancer
AT wanting impactoftheinitialsiteofmetastasesonpostrecurrencesurvivalforneuroendocrinecervicalcancer
AT jiangyinan impactoftheinitialsiteofmetastasesonpostrecurrencesurvivalforneuroendocrinecervicalcancer
AT zhengxiaojing impactoftheinitialsiteofmetastasesonpostrecurrencesurvivalforneuroendocrinecervicalcancer
AT liupingping impactoftheinitialsiteofmetastasesonpostrecurrencesurvivalforneuroendocrinecervicalcancer
AT xianghuiling impactoftheinitialsiteofmetastasesonpostrecurrencesurvivalforneuroendocrinecervicalcancer
AT zhengmin impactoftheinitialsiteofmetastasesonpostrecurrencesurvivalforneuroendocrinecervicalcancer